Population screening for reproductive risk for single gene disorders in Australia: Now and the future

Twin Research and Human Genetics

Volumn 11, Issue 4, 2008, Pages 422-430

  Delatycki, Martin B ^a,b  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b Genetic Health Services Victoria   (Australia)

Author keywords

Carrier; Cystic fibrosis; Screening; Tay Sachs disease; Thalassaemia

Indexed keywords

ALPHA GLOBIN; BETA GLOBIN; FRAGILE X MENTAL RETARDATION PROTEIN; SURVIVAL MOTOR NEURON PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ARTICLE; ATTITUDE TO HEALTH; AUSTRALIA; CULTURAL FACTOR; CYSTIC FIBROSIS; FRAGILE X SYNDROME; GENE MUTATION; GENETIC DISORDER; GENETIC RISK; GENETIC SCREENING; HEALTH BELIEF; HEALTH CARE COST; HEALTH ECONOMICS; HEMOGLOBINOPATHY; HETEROZYGOTE; HUMAN; INFORMED CONSENT; MASS SCREENING; NONHUMAN; POPULATION GENETICS; PREGNANCY; PRENATAL SCREENING; PRIORITY JOURNAL; REPRODUCTION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SCHOOL HEALTH SERVICE; SOCIAL PSYCHOLOGY; SPINAL MUSCULAR ATROPHY; TAY SACHS DISEASE; THALASSEMIA;

AUSTRALIA; CYSTIC FIBROSIS; FEMALE; FRAGILE X SYNDROME; GENETIC DISEASES, INBORN; GENETIC SCREENING; GENETICS, POPULATION; HEMOGLOBINOPATHIES; HETEROZYGOTE DETECTION; HUMANS; INFORMED CONSENT; JEWS; MALE; MUSCULAR ATROPHY, SPINAL; PREGNANCY; RISK FACTORS; TAY-SACHS DISEASE;

EID: 49749101635     PISSN: 18324274     EISSN: None     Source Type: Journal    
DOI: 10.1375/twin.11.4.422     Document Type: Article

References (67)

1. American College of Obstetricians and Gynecologists. (2007). ACOG Practice Bulletin No. 78: Hemoglobinopathies in pregnancy. Obstetrics and Gynecology, 109, 229-237.
2. Andermann, A., Blancquaert, I., Beauchamp, S., & Dery, V. (2008). Revisiting Wilson and Junger in the genomic era: A review of screening criteria over the past 40 years. Bulletin of the World Health Organization, 86, 317-319.
3. Angastiniotis, M., & Modell, B. (1998). Global epidemiology of hemoglobin disorders. Annals of the New York Academy of Sciences, 850, 251-269.
4. Bach, G., Tomczak, J., Risch, N., & Ekstein, J. (2001). Tay-Sachs screening in the Jewish Ashkenazi population: DNA testing is the preferred procedure. American Journal of Medical Genetics, 99, 70-75.
5. Barlow-Stewart, K., Burnett, L., Proos, A., Howell, V., Huq, F., Lazarus, R., & Aizenberg, H. (2003). A genetic screening programme for Tay-Sachs disease and cystic fibrosis for Australian Jewish high school students. Journal of Medical Genetics, 40, e45.
6. Barlow-Stewart, K., Gaff, C., Emery, J., & Metcalfe, S. A. (2007). Family genetics. Australian Family Physician, 36, 802-805.
7. Berkenstadt, M., Ries-Levavi, L., Cuckle, H., Peleg, L., & Barkai, G. (2007). Preconceptional and prenatal screening for fragile X syndrome: experience with 40,000 tests. Prenatal Diagnosis, 27, 991-994.
8. Beutler, E. (2006). Gaucher disease: Multiple lessons from a single gene disorder. Acta Paediatrica, 95(Suppl.), 103-109.
9. Beutler, E. (2007). Carrier screening for Gaucher disease: More harm than good? Journal of the American Medical Association, 298, 1329-1331.
10. Beutler, E., Boggs, D. R., Heller, P., Maurer, A., Motulsky, A. G., & Sheehy, T. W. (1971). Hazards of indiscriminate screening for sickling. New England Journal of Medicine, 285, 1485-1486.
11. Birgens, H., & Ljung, R. (2007). The thalassaemia syndromes. Scandinavian Journal of Clinical and Laboratory Investigation, 67, 11-25.
12. Brady, R. O. (2006). Enzyme replacement for lysosomal diseases. Annual Review of Medicine, 57, 283-296.
13. Burnett, L., Proos, A. L., Chesher, D., Howell, V. M., Longo, L., Tedeschi, V., Yang, V. A., Siafakas, N., & Turner, G. (1995). The Tay-Sachs disease prevention program in Australia: Sydney pilot study. Medical Journal of Australia, 163, 298-300.
14. Chadwick, R., ten Have, H., Husted, J., Levitt, M., McGleenan, T., Shickle, D., & Wiesing, U. (1998). Genetic screening and ethics: European perspectives. Journal of Medicine and Philosophy, 23, 255-273.
15. Childs, B., Gordis, L., Kaback, M..M., & Kazazian, H. H., Jr. (1976). Tay-Sachs screening: Social and psychological impact. American Journal of Human Genetics, 28, 550-558.
16. Christie, L. M., Zilliacus, E. M., Ingrey, A. J., & Turner, G. (2006). Screening couples for cystic fibrosis carrier status: Why are we waiting? Medical Journal of Australian, 184, 477.
17. Coffey, S. M., Cook, K., Tartaglia, N., Tassone, F., Nguyen, D. V., Pan, R., Bronsky, H. E., Yuhas, J., Borodyanskaya, M., Grigsby, J., Doerflinger, M., Hagerman, P. J., & Hagerman, R. J. (2008). Expanded clinical phenotype of women with the FMR1 premutation. American Journal of Medical Genetics, 146, 1009-1016.
18. Cronin, E. K., Normand, C., Henthorn, J. S., Graham, V., & Davies, S. C. (2000). Organisation and cost-effectiveness of antenatal haemoglobinopathy screening and follow up in a community-based programme. British Journal of Obstetrics and Gynaecology, 107, 486-491.
19. Cystic Fibrosis Consortium. (2007). Cystic fibrosis mutation database statistics. Retrieved from http://www.genet.sickkids.on.ca/cftr/ StatisticsPage.html
20. Davies, S. C., Cronin, E., Gill, M., Greengross, P., Hickman, M., & Normand, C. (2000). Screening for sickle cell disease and thalassaemia: A systematic review with supplementary research. Health Technology Assessment, 4, 1-99.
21. Denayer, L., Welkenhuysen, M., Evers-Kiebooms, G., Cassiman, J. J., Van den Berghe, H. (1996). The CF carrier status is not associated with a diminished self-concept or increased anxiety: Results of psychometric testing after at least 1 year. Clinical Genetics, 49, 232-236.
22. Ekstein, J., & Katzenstein, H. (2001). The Dor Yeshorim story: community-based carrier screening for Tay-Sachs disease. Advances in Genetics, 44, 297-310.
23. European Society of Human Genetics. (2003). Population genetic screening programmes: Technical, social and ethical issues. European Journal of Human Genetics, 11, 903-905.
24. Frumkin, A., & Zlotogora, J. (2008). Genetic screening for reproductive purposes at school: Is it a good strategy? American Journal of Medical Genetics, 146, 264-269.
25. Gason, A. A., Metcalfe, S. A., Delatycki, M. B., Petrou, V., Sheffield, E., Bankier, A., & Aitken, M. (2005). Tay Sachs disease carrier screening in schools: Educational alternatives and cheekbrush sampling. Genetics in Medicine, 7, 626-632.
26. Gason, A. A., Sheffield, E., Bankier, A., Aitken, M. A., Metcalfe, S., Barlow-Stewart, K., & Delatycki, M. B. (2003). Evaluation of a Tay-Sachs disease screening program. Clinical Genetics, 63, 386-392.
27. Gordon, C., Walpole, I., Zubrick, S. R., & Bower, C. (2003). Population screening for cystic fibrosis: Knowledge and emotional consequences 18 months later. American Journal of Medical Genetics, 120, 199-208.
28. Haddow, J. E. (1997). Why the term 'carrier screening' should be abandoned. Journal of Medical Screening, 4, 1.
29. Jacquemont, S., Hagerman, R. J., Hagerman, P. J., Leehey, M. A. (2007). Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1. Lancet Neurology, 6, 45-55.
30. Jacquemont, S., Hagerman, R. J., Leehey, M. A., Hall, D. A., Levine, R. A., Brunberg, J. A., Zhang, L., Jardini, T., Gane, L. W., Harris, S. W., Herman, K., Grigsby, J., Greco, C. M., Berry-Kravis, E., Tassone, F., & Hagerman, P. J. (2004). Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. Journal of the Americal Medical Association, 291, 460-469.
31. Kaback, M., Nathan, T., & Greenwald, S. (1997). Tay-Sachs disease: heterozygote screening and prenatal diagnosis. U.S. experience and world perspective. In M. Kaback (Ed.), Tay-Sachs Disease, Screening and Prevention (pp. 13-36). New York: Alan R. Liss.
32. Khoury, M. J., McCabe, L. L., & McCabe, E. R. (2003). Population screening in the age of genomic medicine. New England Journal of Medicine, 348, 50-58.
33. Knoppers, B. M., Bordet, S., & Isasi, R. M. (2006). Preimplantation genetic diagnosis: An overview of socio-ethical and legal considerations. Annual Review of Genomics and Human Genetics, 7, 201-221.
34. Lefebvre, S., Burglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., Le Paslier, D., Frézal, J., Cohen, D., Weissenbach, J., Munnich, A., & Melki, J. (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell, 80, 155-165.
35. Leib, J. R., Gollust, S. E., Hull, S. C., & Wilfond, B. S. (2005). Carrier screening panels for Ashkenazi Jews: is more better? Genetics in Medicine, 7, 185-190.
36. Loeben, G. L., Marteau, T. M., & Wilfond, B. S. (1998). Mixed messages: Presentation of information in cystic fibrosis-screening pamphlets. American Journal of Human Genetics, 63, 1181-1189.
37. Marteau, T., & Anionwu, E. (1996). Evaluating carrier testing: objectives and outcomes. In T. Marteau & M. Richards (Eds.), The troubled helix: Social and psychological implications of the new human genetics. (pp. 123-139). Cambridge: Cambridge University Press.
38. Marteau, T. M., & Drake, H. (1995). Attributions for disability: The influence of genetic screening. Social Science and Medicine, 40, 1127-1132.
39. Marteau, T. M., Dundas, R., & Axworthy, D. (1997). Long-term cognitive and emotional impact of genetic testing for carriers of cystic fibrosis: The effects of test result and gender. Health Psychology, 16, 51-62.
40. Massie, R. J., Delatycki, M. B., & Bankier, A. (2005). Screening couples for cystic fibrosis carrier status: Why are we waiting? Medical Journal of Australia, 183, 501-502.
41. Massie, R. J., Olsen, M., Glazner, J., Robertson, C. F., & Francis, I. (2000). Newborn screening for cystic fibrosis in Victoria: 10 years' experience (1989-1998). Medical Journal of Australia, 172, 584-587.
42. McKusick, V. (2008). Online Mendelian Inheritance in Man. Available at http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim
43. Mennie, M. E., Axworthy, D., Liston, W. A., & Brock, D. J. (1997). Prenatal screening for cystic fibrosis carriers: does the method of testing affect the longer-term understanding and reproductive behaviour of women? Prenatal Diagnosis, 17, 853-860.
44. Metcalfe, S. A., Barlow-Stewart, K., Campbell, J., & Emery, J. (2007). Genetics and blood: Haemoglobinopathies and clotting disorders. Australian Family Physician, 36, 812-819.
45. Mitchell, J. J., Capua, A., Clow, C., & Scriver, C. R. (1996). Twenty-year outcome analysis of genetic screening programs for Tay-Sachs and beta-thalassemia disease carriers in high schools. American Journal of Human Genetics, 59, 793-798.
46. Murray, J., Cuckle, H., Taylor, G., & Hewison, J. (1997). Screening for fragile X syndrome: information needs for health planners. Journal of Medical Screening, 4, 60-94.
47. Nelson, W. B., Swint, J. M., & Caskey, C. T. (1978). An economic evaluation of a genetic screening program for Tay-Sachs disease. American Journal of Human Genetics, 30, 160-166.
48. Ogino, S., Wilson, R.B., & Gold, B. (2004). New insights on the evolution of the SMN1 and SMN2 region: simulation and meta-analysis for allele and haplotype frequency calculations. European Journal of Human Genetics, 12, 1015-1023.
49. Old, J. M. (2007). Screening and genetic diagnosis of haemoglobinopathies. Scandinavian Journal of Clinical and Laboratory Investigation, 67, 71-86.
50. Ostrowsky, J. T., Lippman, A., & Scriver, C. R. (1985). Cost-benefit analysis of a thalassemia disease prevention program. American Journal of Public Health, 75, 732-736.
51. Pearn, J. (1980). Classification of spinal muscular atrophies. Lancet, 1, 919-922.
52. Quinlivan, J. A., & Suriadi, C. (2006). Attitudes of new mothers towards genetics and newborn screening. Journal of Psychosomatic Obstetrics and Gynaecology, 27, 67-72.
53. Radhakrishnan, M., van Gool, K., Hall, J., Delatycki, M., & Massie, J. (2008). Economic evaluation of cystic fibrosis screening: A review of the literature. Health Policy, 85, 133-147.
54. Reiss, A. L., & Hall, S. S. (2007). Fragile X syndrome: assessment and treatment implications. Child and Adolescent Psychiatric Clinics of North America, 16, 663-675.
55. Rommens, J. M., Iannuzzi, M. C., Kerem, B., Drumm, M. L., Melmer, G., Dean, M., Rozmahel, R., Cole, J. L., Kennedy, D., Hidaka, N., Zsiga, M., Buchwald, M., Riordan, J. R., Tsui, L. C., & Collins, F. S. (1989). Identification of the cystic fibrosis gene: Chromosome walking and jumping. Science, 245, 1059-1065.
56. Ross, L. F. (2006). Heterozygote carrier testing in high schools abroad: What are the lessons for the U.S.? Journal of Law, Medicine and Ethics, 34, 753-764.
57. Rowley, P. T., Loader, S., & Kaplan, R. M. (1998). Prenatal screening for cystic fibrosis carriers: an economic evaluation. American Journal of Human Genetics, 63, 1160-1174.
58. Sheeran, P., & Abraham, C. (1996). The health belief model. In M. Connor PN (Ed.). Predicting health behaviour: Research and practice with social cognitions models (pp. 23-61). Buckingham: Oxford University Press.
59. Sher, C., Romano-Zelekha, O., Green, M. S., & Shohat, T. (2003). Factors affecting performance of prenatal genetic testing by Israeli Jewish women. American Journal of Medical Genetics, 120, 418-422.
60. Soini, S., Ibarreta, D., Anastasiadou, V., Ayme, S., Braga, S., Cornel, M., Coviello, D. A., Evers-Kiebooms, G., Geraedts, J., Gianaroli, L., Harper, J., Kosztolanyi, G., Lundin, K., Rodrigues-Cerezo, E., Sermon, K., Sequeiros, J., Tranebjaerg, L., & Kaariainen, H. (2006). The interface between assisted reproductive technologies and genetics: Technical, social, ethical and legal issues. European Journal of Human Genetics, 14, 588-645.
61. Tassone, F., Pan, R., Amiri, K., Taylor, A. K., & Hagerman, P. J. (2008). A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. Journal of Molecular Diagnostics, 10, 43-49.
62. Warren, E., Anderson, R., Proos, A. L., Burnett, L. B., Barlow-Stewart, K., & Hall, J. (2005). Cost-effectiveness of a school-based Tay-Sachs and cystic fibrosis genetic carrier screening program. Genetics in Medicine, 7, 484-494.
63. Watson, M. S., Cutting, G. R., Desnick, R. J., Driscoll, D. A., Klinger, K., Mennuti, M., Palomaki, G. E., Popovich, B. W., Pratt, V. M., Rohlfs, E. M., Strom, C. M., Richards, C. S., Witt, D. R., & Grody, W. W. (2004). Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genetics in Medicine, 6, 387-391.
64. Williams, J. K., & Schutte, D. L. (1997). Benefits and burdens of genetic carrier identification. Western Journal of Nursing Research, 19, 71-81.
65. Wilson, J., & Junger, G. (1968). The principles and practice of screening for disease. In World Health Organisation. Public Health Paper 34. Geneva: World Health Organization.
66. Zeuner, D. (1997). Why the term 'carrier screening' should not be abandoned. Journal of Medical Screening, 4, 176.
67. Zuckerman, S., Lahad, A., Shmueli, A., Zimran, A., Peleg, L., Orr-Urtreger, A., Levy-Lahad, E., & Sagi, M. (2007). Carrier screening for Gaucher disease: Lessons for low-penetrance, treatable diseases. Journal of the American Medical Association, 298, 1281-1290.